Eisai Thyroid Cancer Drug Gets Orphan Drug Status By U.S. FDA
This article was originally published in PharmAsia News
Eisai Pharmaceuticals said its E7080 (lenvatinib) drug for treating thyroid cancer has been given orphan-drug status by U.S. FDA, easing its way through the marketing approval process.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.